Finance News World

Autosomal Dominant Polycystic Kidney Disease Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Autosomal Dominant Polycystic Kidney Disease Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

March 17
14:38 2020
Autosomal Dominant Polycystic Kidney Disease Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

Autosomal Dominant Polycystic Kidney Disease – Market Insights, Epidemiology, and Market Forecast-2030

DelveInsight has launched a new report on Autosomal Dominant Polycystic Kidney Disease Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “Autosomal Dominant Polycystic Kidney Disease – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  1. The prevalence of ADPKD is estimated to range from 1 in 400 to 1000 live births, with 5,000–6,000 new cases diagnosed each year.
  2. The majority prevalent cases of ADPKD were recorded in the United States.
  3. The lowest prevalent population of ADPKD was recorded in Japan.
  4. The prevalence of ADPKD increased with age and reached a peak value of 261 per million population at the age group of 55-59 years.

 

Key benefits of the Report

1. Autosomal Dominant Polycystic Kidney Disease market report covers a descriptive overview and comprehensive insight of the Alzheimer’s disease epidemiology and Autosomal Dominant Polycystic Kidney Disease market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Autosomal Dominant Polycystic Kidney Disease market report provides insights on the current and emerging therapies. 

3. Autosomal Dominant Polycystic Kidney Disease market report offers a global historical and forecasted market covering drug outreach in 7 MM.

4. Autosomal Dominant Polycystic Kidney Disease market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Autosomal Dominant Polycystic Kidney Disease market.

Request for Sample Pages: https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market

 

 

“According to DelveInsight’s analysis, ADPKD is the most common in adults and is most frequent in higher age groups and 50% of ADPKD may progress to ESRD by 60 years of age.”

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic disorder which causes pathological cystic changes to the kidney and is characterized by numerous renal and systemic manifestations. Renal manifestations are produced by the progressive and continuous enlargement and proliferation of fluid-filled cysts, leading to enlargement of the kidney up to five times the normal volume in the years prior to the development of kidney failure.

ADPKD may led to development of end-stage renal disease (ESRD) and is the fourth most common renal disease requiring renal replacement therapy (RRP). The most common extrarenal manifestation is polycystic liver disease (PLD), which is more common in women than in men.

Genetic mutation plays a major role in the pathogenesis of ADPKD, mainly mutations in the PKD1, PKD2 genes leads to cyst formation and its progressive growth.

As per the WHO classification, there are two types of PKD: autosomal dominant (ADPKD) and autosomal recessive (ARPKD). The gene mutations in the PKHD1 gene cause ARPKD, occurring mostly in children.

 “According to DelveInsight, DelveInsight’s Analysis, it can be observed that diagnosis of ADPKD is high in the 7MM.”

Some of the key companies working on Autosomal Dominant Polycystic Kidney Disease are:

  • Sanofi
  • Reata Pharmaceuticals
  • Palladio Biosciences
  • Regulus Therapeutics
  • XORTX Therapeutics

And Many Others.

The launch of the emerging therapies is expected to significantly impact the Autosomal Dominant Polycystic Kidney Disease treatment scenario in the upcoming years:-

 Drugs Covered:

  • Venglustat
  • Bardoxolone
  • Lixivaptan
  • RGLS4326
  • XRx-008

And Many Others.

Request a Free Sample Report @ https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market

 Table of Contents:

1. Report Introduction

2. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Overview at a Glance

2.1. 7 Major Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD) in 2017

2.2. 7 Major Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD) in 2030

3. Disease Background and Overview: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

3.1. Introduction

3.2. Causes

3.3. Pathophysiology

3.4. Symptoms

3.5. Risk Factor

3.6. Diagnosis

4. Epidemiology and Patient Population

4.1. Assumptions and Caveats

4.2. 7MM Prevalent cases of ADPKD (2017–2030)

4.3. Age-Specific cases of ADPKD (2017–2030)

4.4. Diagnosed and Treatable cases of ADPKD (2017–2030)

4.5. Autosomal Dominant Polycystic Kidney Disease (ADPKD): Country-Wise Epidemiology

4.6. United States

4.6.1. Assumptions and Rationale

4.6.2. Prevalent cases of ADPKD (2017–2030))

4.6.3. Age-Specific cases of ADPKD (2017–2030)

4.6.4. Diagnosed and Treatable cases of ADPKD (2017–2030)

4.7. EU-5

4.8. Assumptions and Rationale

4.9. Germany

4.9.1. Prevalent cases of ADPKD (2017–2030)

4.9.2. Age-Specific cases of ADPKD (2017–2030)

4.9.3. Diagnosed and Treatable cases of ADPKD (2017–2030)

4.10. France

4.10.1. Prevalent cases of ADPKD (2017–2030)

4.10.2. Age-Specific cases of ADPKD (2017–2030)

4.10.3. Diagnosed and Treatable cases of ADPKD (2017–2030)

4.11. Italy

4.11.1. Prevalent cases of ADPKD (2017–2030)

4.11.2. Age-Specific cases of ADPKD (2017–2030)

4.11.3. Diagnosed and Treatable cases of ADPKD (2017–2030)

4.12. Spain

4.12.1. Prevalent cases of ADPKD (2017–2030)

4.12.2. Age-Specific cases of ADPKD (2017–2030)

4.12.3. Diagnosed and Treatable cases of ADPKD (2017–2030)

4.13. United Kingdom

4.13.1. Prevalent cases of ADPKD (2017–2030)

4.13.2. Age-Specific cases of ADPKD (2017–2030)

4.13.3. Diagnosed and Treatable cases of ADPKD (2017–2030)

4.14. Japan

4.14.1. Assumptions and Rationale

4.14.2. Prevalent cases of ADPKD (2017–2030)

4.14.3. Age-Specific cases of ADPKD (2017–2030)

4.14.4. Diagnosed and Treatable cases of ADPKD (2017–2030)

5. Treatments & Medical Practices

5.1. Treatment Algorithm

5.2. Treatment Guidelines

5.2. Unmet needs

6. Marketed Therapies 6.1. Jynarque (tolvaptan): Otsuka Pharmaceuticals

6.1.1. Product Description

6.1.2. Mechanism of Action

6.1.3. Regulatory Milestones

6.1.4. Safety and Efficacy

6.1.5. Clinical Trial Information

6.1.6. Advantages and Disadvantages

7. Emerging Therapies

8. Key Cross Competition

8.1. Venglustat: Sanofi

8.1.1. Regulatory Milestones

8.1.2. Clinical Development

8.1.3. Product Profile

8.1.4. Clinical Pipeline Activity

8.1.5. Ongoing Trials Information

8.1.6. Clinical Trial by Phase

8.2. Lixivaptan: Palladio Biosciences

8.2.1. Regulatory Milestones

8.2.2. Clinical Development

8.2.3. Product Profile

8.2.4. Clinical Pipeline Activity

8.2.5. Ongoing Trials Information

8.2.6. Clinical Trial by Phase

8.3. Bardoxolone: Reata Pharmaceuticals

8.3.1. Regulatory Milestones

8.3.2. Clinical Development

8.3.3. Product Profile

8.3.4. Clinical Pipeline Activity

8.3.5. Ongoing Trials Information

8.3.6. Clinical Trial by Phase

8.4. XRx-008: XORTX Therapeutics

8.4.1. Regulatory Milestones

8.4.2. Clinical Development

8.4.3. Product Profile

8.4.4. Clinical Pipeline Activity

8.4.5. Ongoing Trials Information

8.4.6. Clinical Trial by Phase

8.5. RGLS4326: Regulus Therapeutics

8.5.1. Regulatory Milestones

8.5.2. Clinical Development

8.5.3. Product Profile

8.5.4. Clinical Pipeline Activity

8.5.5. Ongoing Trials Information

8.5.6. Clinical Trial by Phase

To be continued in the report…

9. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Size

9.1. Key Findings

9.2. Total 7MM ADPKD Market Analysis

9.3. Overview of Total ADPKD Market

9.4. The market size of ADPKD by 7MM (2017–2030)

10. 7MM Autosomal Dominant Polycystic Kidney Disease (ADPKD): Country-Wise Market Analysis

11. United States Market Size

11.1. Total Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

11.2. Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD) by Therapies

12. Germany Market Size

12.1. Total Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

12.2. Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD) by Therapies

13. France Market Size

13.1. Total Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

13.2. Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD) by Therapies

14. Italy Market Size

14.1. Total Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

14.2. Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD) by Therapies

15. Spain Market Size

15.1. Total Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

15.2. Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD) by Therapies

16. United Kingdom Market Size

16.1. Total Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

16.2. Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD) by Therapies

17. Japan Market Size

17.1. Total Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

17.2. Market Size of Autosomal Dominant Polycystic Kidney Disease (ADPKD) by Therapies

18. Market Drivers

19. Market Barriers

20. Report Methodology

20.1. Sources Used

21. DelveInsight Capabilities

Related Reports:

 Autosomal Dominant Polycystic Kidney Disease – Pipeline Insights, 2020

The Autosomal Dominant Polycystic Kidney Disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Autosomal Dominant Polycystic Kidney Disease across the complete product development cycle, including all clinical and nonclinical stages.

 Autosomal Dominant Polycystic Kidney Disease – Epidemiology Forecast to 2030

The Autosomal Dominant Polycystic Kidney Disease epidemiology covered in the report provides historical as well as forecasted Autosomal Dominant Polycystic Kidney Disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/